IL17A and COVID-19: In conclusion, these studies strongly suggest that these non-biologics do not increase susceptibility or severity of COVID-19, which also confirm the rationality and scientific validity of using them as the control group in this meta-analysis to assess the effect of IL-17 inhibitors on the risk of COVID-19 infection, hospitalization and mortality.